Hodgkin's May Share Common Genetic Mechanism with Multiple Sclerosis

A new study reveals that the same genetic variant raises the risk of developing both Hodgkin's lymphoma and multiple sclerosis (MS).

Researchers from the Institute of Cancer Research (ICR) in London identified a pair of genetic markers that boost the risk of Hodgkin's lymphoma. These markers affect the development of the immune system.

This brings the known number of genetic risk factors for Hodgkin's up to five.

Finding a 'common mechanism'

Said Professor Alan Ashworth, Chief Executive of the ICR:

Our immune systems must strike a fine balance between on the one hand remaining vigilant to infections or abnormalities such as cancer, and on the other not becoming over-active, and attacking the body's own tissues.

The researchers analyzed the genetic make-up of more than 3,400 patients with Hodgkin's and compared them to more than 8,200 people not diagnosed with the disease.

Among the almost three dozen single nucleotide polymorphisms (SNPs), or single letter changes, in DNA that they found may raise one's risk of Hodgkin's, one of them is a known risk factor for MS. This is important because it may show a common mechanism operating behind both diseases.

Added Professor Ashworth:

Cancer appears to be, in part, a disease of an under-active immune system, while autoimmune diseases like multiple sclerosis are caused by the body's immune system working in overdrive and attacking itself.

The study appears in the journal Nature Communications and was funded in part by Cancer Research UK, the largest cancer charity in the United Kingdom.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap